Development of imaging agents for prediction of treatment strategy and severity of dementia and the stress mental disorder

• Project/Area Number: 19591405
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Radiation science
• Research Institution: Kanazawa University
• Principal Investigator: MIZUKAMI Yuji (2009) Kanazawa University, 保健学系, 教授 (60110540); 辻 志郎 (2007-2008) Kanazawa University, 保健学系, 准教授 (70227388)
• Co-Investigator(Kenkyū-buntansha): SHIBA Kazuhiro 金沢大学, 学際科学実験センター, 教授 (40143929) ; 水上 勇治 金沢大学, 保健学系, 教授 (60110540)
• Project Period (FY): 2007 – 2009
• Project Status: Completed (Fiscal Year 2009)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2007: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: ストレス性精神疾患 / シグマ受容体 / 分子イメージング / PET / 認知症 / ストレス性精神神経障害 / SPECT

Research Abstract

学習/記憶と深く係わり、またストレスによる精神障害に対する緩和作用があるシグマ受容体の変化を生体内で可視化することができる放射性シグマ受容体分子イメージング剤であるSPECT用放射性ヨウ素標識(+)p-iodovesamicol((+)-pIV)及びPET用の(+)-[^<11>C]p-methylvesamicol((+)-[^<11>C]PMV)を合成した。両イメージング剤ともシグマ受容体に対する親和性が高く、インビボで脳内のシグマ受容体に選択的に結合していることがわかった。以上のことから、SPECT及びPET用のシグマ受容体イメージング剤を用いた認知症やストレス性障害の早期診断・進行度診断や治療指針予測ができる可能性が示唆された。

Research Products

• [Journal Article] A Change of in Vivo Characteristics Depending on Specific Activity of Radioiodinated (+)-2-[4-(4-iodophenyl) piperidino] cyclohexanol [(+)-pIV] as a Ligand for Sigma Receptor Imaging. (2008)
  • Author(s): Akhter N., Shiba, K., Ogawa, K., S, Tsuji, Kinuya, S., Nakajima, K, Mori
  • Journal Title: Nucl. Med. Biol. 35 Pages: 29-34
  • Peer Reviewed
• [Journal Article] A Change of in Vivo characteristics Depending on Specific Activity of Radioiodinated (+)-2-[4-(4-iodophenyl) piperldino] cyclohexanol [(+)-pIV] as a Ligand for Sigma Receptor Imaging. (2008)
  • Author(s): Nasima Akhter
  • Journal Title: Nucl. Med. Biol 35 Pages: 29-34
  • Peer Reviewed
• [Journal Article] In vivo Characterization of Radioiodinated (+)-2-[4-(4-iodophenyl) piperidino] cyclohexanol [(+)-pIV] as a potential sigma-1 receptor imaging agent. (2007)
  • Author(s): Akhter, N., Shiba, K., Ogawa, K., Kinuya, S., Nakajima, K, Mori, H.
  • Journal Title: Nucl. Med. Biol. 34 Pages: 697-702
  • Peer Reviewed
• [Presentation] pet及びspect用インビボ分子イメージング剤の開発研究-脳神経機能の可視化を目指して- (2009)
  • Author(s): 柴和弘
  • Organizer: 富山大学生命科学先端研究センター学術セミナー
  • Place of Presentation: 富山市(富山県)
  • Year and Date: 2009-11-24
• [Presentation] Biodistribution and metabolic studies of a radioiodinated vesamicol analog as a sigma receptor ligand for tumor imaging. (2009)
  • Author(s): Ogawa, K., Akhter, N., Shiba, K
  • Organizer: 18th International Symposium on Radiopharmaceutical Sciences.
  • Place of Presentation: Edmonton (Canada)
• [Presentation] Influence of different metabolic function by the species specificity in the biodistribution of radiolabeled sigma ligand as a tumor seeking agent. (2008)
  • Author(s): Akhter, N., Shiba, K. Ogawa, K., Tsuji, S., Nakajima, K., Kinuya, S., Mori, H
  • Organizer: 55th SNM Annual Meeting of the Society of Nuclear Medicine.
  • Place of Presentation: New Orleans, LA (USA)
• [Presentation] Depending on Species Specificity Influence of Difference Metabolic Function in the Biodistribution of Radiolabeled Sigma Ligand as the Tumor Seeking Agent. (2008)
  • Author(s): Akhter, N., Shiba, K. Ogawa, K., Tsuji, S., Nakajima, K., Kinuya, S., Mori, H
  • Organizer: 38th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine 2008.
  • Place of Presentation: Gold Coast (Australia)
• [Presentation] In-vivo characteristics of high and low specific activity radioiodinated (+)-2-[4-(4-iodophenyl) piperidino] cyclohexanol [(+)-pIV] for imaging sigma-1 receptor in brain. (2007)
  • Author(s): Akhter, N., Shiba, K. Ogawa, K., Tsuji, S., Nakajima, K., Kinuya, S., Mori, H
  • Organizer: INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY (ICRT-2007)
  • Place of Presentation: Ulaanbaatar (Mongolia)